UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. REDDY'S LABORATORIES, INC.

Petitioner,

v.

CELGENE CORP.

Patent Owner.

CASE NO. IPR2018-01504

Patent No. 9,056,120

DECLARATION OF MARK LEVIN, M.D., IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 9,056,120

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF CONTENTS

Page

I. QUALIFICATIONS AND BACKGROUND 5

A. Education and Experience 5

B. Materials Considered 9

C. Scope of Work 9

II. SUMMARY OF OPINIONS 10

III. LEGAL STANDARDS 12

IV. PERSON OF ORDINARY SKILL IN THE ART 15

V. BACKGROUND 16

A. MDS and Its Classification and Treatment 16

B. Thalidomide 27

C. Lenalidomide 29

VI. SCOPE AND CONTENT OF THE PRIOR ART REFERENCES 34

A. TNFα Was a Focus for MDS Treatment 36

1. Shetty 1996 [Ex. 1015] 37

B. Thalidomide Clinical Trials in MDS Were Successful and Promising 38

1. Raza 2000b [Ex. 1021] 38

2. Raza 2000d [Ex. 1022] 39

3. Raza 2001 [Ex. 1023] 41

4. Thomas 2000a [Ex. 1005] 44

C. A POSA Had Knowledge of Revimid 46

1. Thomas 2000a [Ex. 1005] 48

2. Corral 1999b [Ex. 1016] 49

3. Marriott 2001 [Ex. 1017] 51

4. Celgene Press Release 8/28/2001 [Ex. 1010] 54

5. The ’230 patent [Ex. 1006] 56

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF CONTENTS
(continued)

Page

D. A POSA Had Knowledge of the Clinical Administration of Revimid 58

1. List 2001 [Ex. 1004] 58

2. Ritter 2001 [Ex. 1014] 59

3. Celgene Press Release 5/8/2001 [Ex. 1008] 60

4. Celgene Press Release 6/7/2001 [Ex. 1009] 63

VII. THE CONTESTED CLAIMS OF THE '120 PATENT ARE UNPATENTABLE 65

A. Ground 1: Claims 1–8, 12–34, and 38–53 were unpatentable as obvious over List 2001 in view of the '230 patent and the Celgene Press Releases 5/8/2001 and 8/28/2001 70

1. Claims 1 and 28 were unpatentable as obvious over List 2001 in view of the '230 patent and the Celgene Press Releases 5/8/2001 and 8/28/2001 72

a. Use of Revimid to treat MDS and MDS-caused TDA 72

b. Revimid's chemical name and structure 77

c. Administration of about 1–25 mg/day Revimid to treat MDS and MDS-caused TDA 79

2. Dependent claim 2 was obvious 87

3. Dependent claims 3–6 and 29–32 were obvious 89

4. Dependent claims 16–21 and 42–47 were obvious 91

5. Dependent claims 24–27 and 50–53 were obvious 94

6. Dependent claims 7–8 and 33–34 were obvious 96

7. Dependent claims 12 and 38 were obvious 98

8. Dependent claims 13–15, 22–23, 39–41, and 48–49 were obvious 99

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF CONTENTS
(continued)

Page

B. Ground 2: Claims 1–8, 12–34, and 38–53 were unpatentable as obvious over Thomas 2000a in view of the '230 patent and the Celgene Press Releases 5/8/2001 and 8/28/2001 107

1. Claims 1 and 28 were unpatentable as obvious over Thomas 2000a in view of the '230 patent and the Celgene Press Releases 5/8/2001 and 8/28/2001 109

a. Use of lenalidomide (and thalidomide) to treat MDS-caused TDA 109

b. Revimid chemical name and structure 114

c. Administration of about 1–25 mg/day Revimid to treat MDS and MDS-caused TDA 115

2. Dependent claim 2 was obvious 118

3. Dependent claims 3–6 and 29–32 were obvious 119

4. Dependent claims 16–21 and 42–47 were obvious 121

5. Dependent claims 24–27 and 50–53 were obvious 122

6. Dependent claims 7–8 and 33–34 were obvious 123

7. Dependent claims 12 and 38 were obvious 124

8. Dependent claims 13–15, 22–23, 39–41, and 48–49 were obvious 125

VIII. CONCLUSION 128

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

I. QUALIFICATIONS AND BACKGROUND

A. Education and Experience

1. My name is Mark Levin. I am a medical oncologist with 28 years of experience treating patients with myelodysplastic syndrome and multiple myeloma. Throughout my career, I have engaged in clinical research, including writing and conducting clinical trials, writing papers, and performing clinical as well as administrative work related to cancer medicine in a variety of settings. My full curriculum vitae (CV) is attached hereto as Exhibit A and is incorporated herein.

2. I received a Bachelor's degree in Pre-Medical Studies from Yeshiva University in 1980. I received my M.D. from State University of New York (SUNY) in Brooklyn in 1984. I later completed an M.B.A. program from the Herriott-Watt University, Edinburgh Business School, in 2005.

3. After graduating from medical school, I completed my internship at Hahnemann University Medical Center (now Drexel University College of Medicine) in 1985–1986 and my residency in Internal Medicine at New York Downtown Hospital in New York City from 1986–1987. Afterward, from 1987–1990, I completed a three-year program in Hematology and Oncology at the Long Island Jewish Hillside Hospital Medical Center, in New Hyde Park, New York.

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.